These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22608016)

  • 21. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
    Enzensberger C; Eskef K; Schwarze A; Faas D; Axt-Fliedner R
    Ultraschall Med; 2012 Oct; 33(5):493-6. PubMed ID: 21630188
    [No Abstract]   [Full Text] [Related]  

  • 23. Olmesartan-induced enteropathy.
    Heerasing N; Hair C; Wallace S
    Intern Med J; 2015 Jan; 45(1):117-8. PubMed ID: 25582943
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
    Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
    Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract]   [Full Text] [Related]  

  • 27. [Multicenter trial of olmesartan. Main results].
    Ageev FT; Svirida ON
    Ter Arkh; 2011; 83(9):54-60. PubMed ID: 22145389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-/T-type Ca channel blockers for kidney protection: ready for sophisticated use of Ca channel blockers.
    Hayashi K
    Hypertens Res; 2011 Aug; 34(8):910-2. PubMed ID: 21753772
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes: ROADMAP: the road to renoprotection?
    Roscioni SS; Heerspink HJ; de Zeeuw D
    Nat Rev Nephrol; 2011 May; 7(8):427-8. PubMed ID: 21610679
    [No Abstract]   [Full Text] [Related]  

  • 31. [Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus].
    Lancellotti P
    Rev Med Liege; 2007 Mar; 62(3):175-9. PubMed ID: 17511387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
    Nesbitt SD; Shojaee A; Maa JF; Weir MR
    J Hum Hypertens; 2013 Jul; 27(7):445-52. PubMed ID: 23254596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial: sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers--the plot thickens.
    Lebwohl B; Ludvigsson JF
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1245-6. PubMed ID: 25303379
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris.
    Ishii H; Kobayashi M; Kurebayashi N; Yoshikawa D; Suzuki S; Ichimiya S; Kanashiro M; Sone T; Tsuboi H; Amano T; Uetani T; Harada K; Marui N; Murohara T
    Am J Cardiol; 2013 Aug; 112(3):363-8. PubMed ID: 23623047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
    Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Murakami M; Hirose E; Sato S; Ohkawa K; Ishizawa M; Yamaji H; Kawamura H; Kusachi S; Murakami T; Hina K; Ohe T
    J Am Coll Cardiol; 2010 Mar; 55(10):976-82. PubMed ID: 20202514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plaque burden with composition? That is the next question.
    Marso SP
    J Am Coll Cardiol; 2010 Mar; 55(10):983-5. PubMed ID: 20202515
    [No Abstract]   [Full Text] [Related]  

  • 38. Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) extension trial.
    Hirohata A; Yamamoto K; Miyoshi T; Hatanaka K; Hirohata S; Yamawaki H; Komatsubara I; Hirose E; Kobayashi Y; Ohkawa K; Ohara M; Takafuji H; Sano F; Toyama Y; Kusachi S; Ohe T; Ito H
    Atherosclerosis; 2012 Jan; 220(1):134-8. PubMed ID: 22119063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
    Oparil S; Chrysant SG; Melino M; Lee J; Karki S; Heyrman R
    J Hum Hypertens; 2010 Dec; 24(12):831-8. PubMed ID: 20200547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of olmesartan for ≥ 1 year was associated with hospitalization for intestinal malabsorption.
    Talley NJ
    Ann Intern Med; 2015 Dec; 163(12):JC13. PubMed ID: 26666803
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.